Cargando…

Proteomic profiling of human amnion for preterm birth biomarker discovery

Spontaneous preterm birth (PTB) complicates about 12% of pregnancies worldwide, remaining the main cause of neonatal morbidity and mortality. Spontaneous preterm birth PTBs is often caused by microbial-induced preterm labor, mediated by an inflammatory process threatening both maternal and newborn h...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruschi, Maurizio, Bartolucci, Martina, Petretto, Andrea, Buffelli, Francesca, Kajana, Xhuliana, Parodi, Alessandro, Carbone, Riccardo, Fulcheri, Ezio, Ramenghi, Luca Antonio, Panfoli, Isabella, Candiano, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633292/
https://www.ncbi.nlm.nih.gov/pubmed/34848816
http://dx.doi.org/10.1038/s41598-021-02587-3
_version_ 1784607897138757632
author Bruschi, Maurizio
Bartolucci, Martina
Petretto, Andrea
Buffelli, Francesca
Kajana, Xhuliana
Parodi, Alessandro
Carbone, Riccardo
Fulcheri, Ezio
Ramenghi, Luca Antonio
Panfoli, Isabella
Candiano, Giovanni
author_facet Bruschi, Maurizio
Bartolucci, Martina
Petretto, Andrea
Buffelli, Francesca
Kajana, Xhuliana
Parodi, Alessandro
Carbone, Riccardo
Fulcheri, Ezio
Ramenghi, Luca Antonio
Panfoli, Isabella
Candiano, Giovanni
author_sort Bruschi, Maurizio
collection PubMed
description Spontaneous preterm birth (PTB) complicates about 12% of pregnancies worldwide, remaining the main cause of neonatal morbidity and mortality. Spontaneous preterm birth PTBs is often caused by microbial-induced preterm labor, mediated by an inflammatory process threatening both maternal and newborn health. In search for novel predictive biomarkers of PTB and preterm prelabor rupture of the membranes (pPROM), and to improve understanding of infection related PTB, we performed an untargeted mass spectrometry discovery study on 51 bioptic mid zone amnion samples from premature babies. A total of 6352 proteins were identified. Bioinformatics analyses revealed a ranked core of 159 proteins maximizing the discrimination between the selected clinical stratification groups allowing to distinguish conditions of absent (FIR 0) from maximal Fetal Inflammatory Response (FIR 3) stratified in function of Maternal Inflammatory Response (MIR) grade. Matrix metallopeptidase-9 (MMP-9) was the top differentially expressed protein. Gene Ontology enrichment analysis of the core proteins showed significant changes in the biological pathways associated to inflammation and regulation of immune and infection response. Data suggest that the conditions determining PTB would be a transversal event, secondary to the maternal inflammatory response causing a breakdown in fetal-maternal tolerance, with fetal inflammation being more severe than maternal one. We also highlight matrix metallopeptidase-9 as a potential predictive biomarker of PTB that can be assayed in the maternal serum, for future investigation.
format Online
Article
Text
id pubmed-8633292
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-86332922021-12-03 Proteomic profiling of human amnion for preterm birth biomarker discovery Bruschi, Maurizio Bartolucci, Martina Petretto, Andrea Buffelli, Francesca Kajana, Xhuliana Parodi, Alessandro Carbone, Riccardo Fulcheri, Ezio Ramenghi, Luca Antonio Panfoli, Isabella Candiano, Giovanni Sci Rep Article Spontaneous preterm birth (PTB) complicates about 12% of pregnancies worldwide, remaining the main cause of neonatal morbidity and mortality. Spontaneous preterm birth PTBs is often caused by microbial-induced preterm labor, mediated by an inflammatory process threatening both maternal and newborn health. In search for novel predictive biomarkers of PTB and preterm prelabor rupture of the membranes (pPROM), and to improve understanding of infection related PTB, we performed an untargeted mass spectrometry discovery study on 51 bioptic mid zone amnion samples from premature babies. A total of 6352 proteins were identified. Bioinformatics analyses revealed a ranked core of 159 proteins maximizing the discrimination between the selected clinical stratification groups allowing to distinguish conditions of absent (FIR 0) from maximal Fetal Inflammatory Response (FIR 3) stratified in function of Maternal Inflammatory Response (MIR) grade. Matrix metallopeptidase-9 (MMP-9) was the top differentially expressed protein. Gene Ontology enrichment analysis of the core proteins showed significant changes in the biological pathways associated to inflammation and regulation of immune and infection response. Data suggest that the conditions determining PTB would be a transversal event, secondary to the maternal inflammatory response causing a breakdown in fetal-maternal tolerance, with fetal inflammation being more severe than maternal one. We also highlight matrix metallopeptidase-9 as a potential predictive biomarker of PTB that can be assayed in the maternal serum, for future investigation. Nature Publishing Group UK 2021-11-30 /pmc/articles/PMC8633292/ /pubmed/34848816 http://dx.doi.org/10.1038/s41598-021-02587-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bruschi, Maurizio
Bartolucci, Martina
Petretto, Andrea
Buffelli, Francesca
Kajana, Xhuliana
Parodi, Alessandro
Carbone, Riccardo
Fulcheri, Ezio
Ramenghi, Luca Antonio
Panfoli, Isabella
Candiano, Giovanni
Proteomic profiling of human amnion for preterm birth biomarker discovery
title Proteomic profiling of human amnion for preterm birth biomarker discovery
title_full Proteomic profiling of human amnion for preterm birth biomarker discovery
title_fullStr Proteomic profiling of human amnion for preterm birth biomarker discovery
title_full_unstemmed Proteomic profiling of human amnion for preterm birth biomarker discovery
title_short Proteomic profiling of human amnion for preterm birth biomarker discovery
title_sort proteomic profiling of human amnion for preterm birth biomarker discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8633292/
https://www.ncbi.nlm.nih.gov/pubmed/34848816
http://dx.doi.org/10.1038/s41598-021-02587-3
work_keys_str_mv AT bruschimaurizio proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT bartoluccimartina proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT petrettoandrea proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT buffellifrancesca proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT kajanaxhuliana proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT parodialessandro proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT carbonericcardo proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT fulcheriezio proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT ramenghilucaantonio proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT panfoliisabella proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery
AT candianogiovanni proteomicprofilingofhumanamnionforpretermbirthbiomarkerdiscovery